Issue release date: 12.11.2024
2Selcuk University, Faculty of Medicine, Department of Neurosurgery, Konya, Turkey
3Selcuk University, Faculty of Medicine, Department of Pathology, Konya, Turkey
4Neuroscience Institute, Hamad Medical Corporation, Department of Neuroradiology, Doha, Qatar
5Qatar University, Professor of Neuroradiology, Doha, Qatar DOI : 10.5137/1019-5149.JTN.36166-21.4 AIM: To explore the ability of dynamic susceptibility contrast perfusion imaging (DSC-PI) to detect isocitrate dehydrogenase (IDH) gene mutation in gliomas.
MATERIAL and METHODS: Preoperative DSC-PI data on histopathologically proven gliomas obtained between January 2015 and December 2019 were reviewed retrospectively. All magnetic resonance imaging (MRI) examinations were performed using a 1.5-T scanner. The maximum relative cerebral blood volume (rCBVmax), percentage signal recovery (PSR), and normalized PSR of tumor cores were calculated. Differences in these values between IDH-mutant and wild-type gliomas were compared, and receiver operating characteristic curves were generated.
RESULTS: The patients (32 females, 47 males) were aged 21-76 years (mean 50.7 ± 15 years). The rCBVmax and all PSR values differed significantly between patients with IDH-mutant and those with wild-type tumors (p<0.01 for all comparisons).
CONCLUSION: The rCBVmax and PSR values obtained by DSC-PI may facilitate noninvasive detection of the IDH mutation status of gliomas. PSR provided more reliable values for differentiation of IDH-mutant gliomas from wild-type gliomas.
Keywords : Perfusion, Magnetic resonance imaging, Glioma, Isocitrate dehydrogenase, Mutation